FDA Clears Path for Haduvio, But Trevi’s “Safe” Two-Trial Plan Sends TRVI Down

Trevi Therapeutics shares plunged despite positive FDA alignment for Haduvio in IPF chronic cough. Plans for two Phase 3 trials (instead of one) triggered sell-off; Stifel holds Buy rating on the de-risked program.